 BOSTON--BUSINESS WIRE--TransCode Therapeutics, Inc. Nasdaq: RNAZ TransCode or the Company, an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today announced the closing of its initial public offering of 7,187,500 shares of its common stock at a public offering price of 4.00 per share. Gross proceeds from the offering totaled 28,750,000, before deducting underwriting discounts 